

Press release
May 4, 2007
Gothenburg, Sweden

Report from Annual General Meeting

At Vitrolife's Annual General Meeting yesterday, May 3, the following, amongst other things, was decided:

- No dividend will be paid for the financial year 2006.
- Re-election of Board members Patrik Tigerschiöld, Madeleine Olsson-Eriksson and Semmy Rülff and new election of Fredrik Mattsson, in accordance with the election committee's proposal.
- Öhrlings PricewaterhouseCoopers was elected as the new auditor, with the authorized public accountant Birgitta Granquist with the main responsibility, for a mandate period of four years.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,900,000 shares in total, corresponding to approximately 9.6 percent of the company's share capital. The issue may deviate from the shareholders' pre-emptive rights through a non-cash issue, through offsetting or may otherwise be subscribed for in accordance with chapter 13 § 5, paragraph one, 6, of the Companies Act. The reason for the possible deviation from the shareholders' pre-emptive rights is to prepare the ground for a possible company acquisition.
- The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition of the company's own shares.
- The proposed principles for remuneration and other conditions of employment for the senior management were approved.

At the Board meeting following election which was held after the Annual General Meeting, Patrik Tigerschiöld was elected Chairman of the Board.

May 4, 2007
Gothenburg, Sweden

The Board

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 120 employees and the company's products are sold in more than 80 markets. The head office is in Kungälv, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.